ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Racial and ethnic disparities in faricimab injections: a propensity matched cohort study.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate potential racial and ethnic disparities in the utilization of faricimab-svoa in the management of macular edema (ME) and neovascular age-related macular degeneration (nAMD).
methodsA retrospective cohort study using the TriNetX database analyzed patients diagnosed with nAMD, type 2 diabetes with diabetic macular edema (DME), or retinal vein occlusion macular edema (RVO ME), grouped by Hispanic ethnicity, African American (AA) race, and non-Hispanic, non-AA controls. Propensity score matching was conducted for age, gender, diabetes mellitus, essential hypertension, obesity, ischemic heart disease, and atherosclerotic heart disease. The primary outcome was faricimab-svoa injection incidence at any time point after diagnosis. Odds ratios (ORs) were calculated between cohorts.
resultsOf 49,568 AA patients (mean [SD] age at injection, 68.3 [14.4] years; 58.5% women) with a diagnosis of nAMD or ME, 55 received faricimab injection (OR 0.162; 95% CI, 0.122-0.215) compared to 338 in the control group of the same size. A similar relationship was noted for Hispanic patients (mean [SD] age at injection, 66.6 [13.5] years; 50.1% women) who received the injection (25 of 13,520) compared to non-Hispanic patients (91 of 13,520) (OR 0.273; 95% CI, 0.176-0.426).
conclusionFaricimab is underutilized in the management of ME and nAMD in patients with AA race and Hispanic ethnicity compared to propensity score matched controls.
Indexed as
Identifiers
42570084What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.